deferoxamine has been researched along with Respiration Disorders in 1 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Respiration Disorders: Diseases of the respiratory system in general or unspecified or for a specific respiratory disease not available.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We conclude that iron-chelation therapy with DFO at the above dosage results in a significant deterioration in cardiovascular function in septic swine." | 5.29 | Deferoxamine induces hypotension in experimental gram-negative septicemia. ( Bohnen, JM; Mullen, JB; Mustard, RA; Schouten, BD; Swanson, HT, 1994) |
| " We conclude that iron-chelation therapy with DFO at the above dosage results in a significant deterioration in cardiovascular function in septic swine." | 1.29 | Deferoxamine induces hypotension in experimental gram-negative septicemia. ( Bohnen, JM; Mullen, JB; Mustard, RA; Schouten, BD; Swanson, HT, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mustard, RA | 1 |
| Bohnen, JM | 1 |
| Mullen, JB | 1 |
| Schouten, BD | 1 |
| Swanson, HT | 1 |
1 other study available for deferoxamine and Respiration Disorders
| Article | Year |
|---|---|
Deferoxamine induces hypotension in experimental gram-negative septicemia.
Topics: Animals; Deferoxamine; Disease Models, Animal; Gram-Negative Bacterial Infections; Hemodynamics; Hyp | 1994 |